重组人血小板生成素注射液和艾曲泊帕乙醇胺片二线治疗原发免疫性血小板减少症的成本-效用分析
x

请在关注微信后,向客服人员索取文件

篇名: 重组人血小板生成素注射液和艾曲泊帕乙醇胺片二线治疗原发免疫性血小板减少症的成本-效用分析
TITLE: Cost-utility analysis of Recombinant human thrombopoietin injection and Etrapopa ethanolamine tablets in the second-line treatment of primary immune thrombocytopenia
摘要: 目的 评估重组人血小板生成素注射液(简称“rhTPO”)对比艾曲泊帕乙醇胺片(简称“艾曲泊帕”)在中国原发免疫性血小板减少症(ITP)成人患者二线治疗中的经济性。方法基于嵌入决策树的马尔可夫模型,以4周为循环周期,从卫生体系角度对患者使用2种药物后的出血事件、不良事件等有关成本和效用进行测算和比较。研究时限为12周,不对成本和健康产出贴现。结果rhTPO较艾曲泊帕提高了0.0025质量调整生命年,并减少了成本1824.36元,为绝对优势方案。单因素敏感性分析结果显示,维持期rhTPO、艾曲泊帕用量对结果的影响较大,但多数情况下rhTPO较艾曲泊帕更具有经济性;概率敏感性分析结果显示,当意愿支付阈值在0~25万元间变动时,rhTPO具有经济性的概率为99.90%~100%。结论在现有证据下,rhTPO相较艾曲泊帕用于二线治疗ITP在短期内更具有经济性。
ABSTRACT: OBJECTIVE To evaluate the econo mical efficiency of Recombinant human thrombopoietin injection (called “rhTPO”for short )versus Etrapopa ethanolamine tablets (called“Etrapopa”for short )in the second-line treatment of primary immune thrombocytopenia (ITP)in the Chinese adult patients. METHODS Based on the decision tree-embedded Markov model with a 4-week cycle ,the cost and utility related to bleeding events and adverse events after the use of the two drugs were measured and compared from the perspective of Chinese health system. The horizon was 12 weeks,and the cost and health outcome were not discounted. RESULTS Compared with Etrapopa ,rhTPO improved the quality adjusted life year by 0.002 5 and reduced the cost by 1 824.36 yuan,which was the absolute advantage scheme. Univariate sensitivity analysis showed that the base results were greatly affected by the dosage of rhTPO and Etrapopa during maintainance period. In most cases ,rhTPO was economical. Probability sensitivity analysis showed that when willingness-to-pay threshold varied between 0 yuan and 250 000 yuan,the probability about that rhTPO was economical ranges from 99.90% to 100%. CONCLUSIONS Based on the available evidence ,rhTPO is more economical in the short term than Etrapopa in the second-line treatment of ITP.
期刊: 2022年第33卷第09期
作者: 经天宇,刘海娇,刘朝一
AUTHORS: JING Tianyu ,LIU Haijiao ,LIU Chaoyi
关键字: 重组人血小板生成素注射液;艾曲泊帕乙醇胺片;原发免疫性血小板减少症;成本-效用分析
KEYWORDS: Recombinant human thrombopoietin injection ;Etrapopa ethanolamine tablet ;primary immune thrombocytopenia ;
阅读数: 21 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!